뉴스

Emma Barnett: Fighting Endometriosis review – this woman is not about to be fobbed off

The BBC presenter has a horrific illness which leaves her and so many other women in a lifelong hell with no cure in sight. Barnett is at the absolute end of her tether … can she change millions of lives? Endometriosis is like someone taking a drill to your organs. The pain resembles a tsunami in every one of your cells – or the movement of tectonic plates inside your body. Years spent contending with the condition is “not life”. Endometriosis may not literally kill you, but suffering from it can feel like a living death. In Emma Barnett: Fighting Endometriosis, the Today presenter provides all these unflinching insights and many more into the condition, which involves cells resembling those that line the uterus growing elsewhere in the body. There is no cure, the only available treatment is hormones (predominantly the contraceptive pill), to mask symptoms, or surgery – including a total hysterectomy, although that won’t necessarily provide relief on a permanent basis. Endometriosis is extremely painful and little understood. It’s also incredibly common: one in 10 women of reproductive age in the UK have it. Continue reading...

Smart drug that strips cancer cells of ‘invisibility cloak’ can shrink tumours by 30%, trial shows

Experimental tablet produces encouraging results in patients with world’s most common forms of disease • ‘I was getting ready to say goodbye’: patient’s hope after smart drug success A smart drug that stops cancer cells “hiding” from treatment can shrink tumours by at least 30% in six of the world’s most common forms of the disease, early trial results show. While immunotherapy treatments have improved survival rates for many patients, their effectiveness can stall or fail when tumour cells hide and then spread. Continue reading...

‘I was getting ready to say goodbye’: cancer patient’s hope after smart drug success

Pat Brogan preparing to walk his daughter down the aisle after trial of treatment designed to stop disease from hiding • Smart drug that strips cancer cells of ‘invisibility cloak’ can shrink tumours by 30%, trial shows One of the first patients to benefit from a pioneering smart drug that appears to melt away the “invisibility cloak” that can shield cancer cells from treatment is Pat Brogan, from Cowdenbeath, Scotland. The 68-year-old, whose tumours have shrunk by almost a third, is preparing to walk his daughter down the aisle this month and holiday in Spain with his wife, Linda – milestones he once feared he would never reach. Continue reading...

388 cells on 2 floors, this cemetery beats the space crunch in Vallakkunnu

West Africa: Nigeria's Anti-Terror Campaign and Ukraine's Robot War

[This Day] For over a decade, Nigeria has been locked in a gruelling war of attrition. From the blood-soaked plains of the Northeast, where Boko Haram and ISWAP splinter cells mutate, to the dense forests of the Northwest, Middle Belt and South West, where ruthless bandit cartels execute mass kidnappings with impunity, the nation is bleeding.

대전환경단체 "대전 갑천 수상레포츠 체험장 운영 재검토해야"

대전지역 환경단체들이 갑천 수상레포츠 체험장 일대에서 조류경보제 '경계' 수준의 녹조가 확인됐다며 체험장 운영 재검토와 도룡가동보 운영 중단을 촉구하고 나섰다. 대전환경운동연합과 대전충남녹색연합은 1일 공동으로 성명을 내고 "갑천 수상레포츠 체험장 운영을 재검토하고, 녹조 확산을 초래한 갑천 도룡가동보 운영을 중단하라"고 대전시에 촉구했다. 두 단체에 따르면, 이들은 지난 5월 8일 갑천 수상레포츠 체험장 일대에서 녹조 모니터링을 진행했다. 현장에서 채수한 시료를 경북대학교 이승준 교수팀에 분석 의뢰한 결과, 남조류 세포수가 18만4000cells/mL에 달하는 것으로 확인됐다. 이는 물환경보전법 시행령에 따른 친수구간 조류경보제 기준상 '경계' 단계에 해당하는 수준이다. 조류경보는 남조류 세포수가 2회 연속 2만cells/mL 이상일 경우 '관심', 2회 연속 10만cells/mL 이상일 경우 '경계' 단계가 발령된다. 전체 내용보기

Heatwave makes conditions 'inhumane', say inmates at overcrowded Paris suburb prison

A damp towel hangs from a barred window, a fan churns the muggy air: Inmates at the overcrowded Villepinte prison outside Paris say enduring a heatwave that has stifled France in recent days in cramped cells is "inhumane".

‘This isn’t wacky science’: Australian researchers teach brain cells to play ‘Doom’ on next‑gen bio‑computer

MELBOURNE, May 31 — Australian researchers have trained lab-grown brain cells on a silicon computer chip to play t...

Australian researchers teach brain cells to play 'Doom'

In this photo taken on May 5, 2026, research scientist Daria Kornienko places cortical and hippocampal cells on a cell culture plate into a CL1 unit before being placed in server racks and available to study via the internet, at Cortical Labs' Physical Containment Level 2 laboratory in...

Australian researchers teach brain cells to play ’Doom’ video game

Each so-called "biological computer" contains around 200,000 living human brain cells, grown from stem cells that were harvested from blood donations.

Heatwave makes conditions 'inhumane', say inmates at overcrowded Paris suburb prison

A damp towel hangs from a barred window, a fan churns the muggy air: Inmates at the overcrowded Villepinte prison outside Paris say enduring a heatwave that has stifled France in recent days in cramped cells is "inhumane".

More women involved in drug trafficking than men in Faisalabad

LAHORE: The Faisalabad City police are going to launch a major operation against drug cartels after the arrest of 80 women and 20 male traffickers who were supplying narcotics to university and college students. Police reports have revealed that the women traffickers dominate the city as they are perceived as less suspicious than men. During interrogation, the suspects revealed that they were supplying drugs through several ‘supplier networks’ to education institutions. The drugs are being routed through district Jhang from Sindh and KP and some groups are working under political backing. The use of internet and social media has become popular for trafficking synthetic drugs. An official said the anti-narcotics cells of the Faisalabad City police arrested 80 women smugglers during the last five months and a majority of them were operating in urban hubs, exclusively targeting students and children of the elite for supply of ice and cocaine. Women traffickers were used to supply drugs in education institutions and hostels. During the last five months, police lodged 4,700 FIRs against the drug suppliers. Ninety percent cases were registered under section 9(c) (non-bailable offence) of the Control of Narcotic Substances Act (CNSA). Faisalabad police arrested 80 women, 20 men for trafficking in last few months “The supply of ice and cocaine by women smugglers to the education institutions had posed a potential challenge for police,” Faisalabad Regional Police Officer (RPO) Sohail Akhtar Sukhera told Dawn. He said the role of women drug cartels, especially their backing by the highly influential bigwigs, was a matter of concern. Some leading lady drug traffickers were identified as Shehnaz alias Cheeno, Suraya, Rabia Dogar, Saira Pathani, etc, he said. The female smugglers had created their respective drug empires across Faisalabad, the DIG said, adding that the arrest of women traffickers helped them secure a majority of the education institutions and students. The male big drug distributors marked by the police included Hamza alias Kamoka, Sunil Dogar, Riaz, Nadeem, Waseem, Shahzad etc. The RPO said that a majority of the drugs was being smuggled through the goods transport. He added that the police had also engaged the prosecution department to ensure punishments to the criminals. He said police had obtained the details of the social media accounts and the phone numbers of the drug traffickers. “The police teams are all set to launch fresh crackdowns,” the RPO said, adding that police would also seek cooperation of Nadra and other relevant institutions to reach the criminals. Published in Dawn, May 30th, 2026

Molecule glue drugs shake up cancer care

One of the biggest advances in pancreatic cancer in decades came out of a crazy idea born in a Harvard University lab.Chemical biologist Gregory Verdine believed you could fight disease-causing proteins hidden inside cells by chemically gluing them to something else in the body and smothering them."Everybody told us this is crazy, that it would never work," he recalls.Revolution Medicines, which bought one of Verdine's companies in 2018, recently announced that one of its drugs doubled the typical survival time for patients with aggressive forms of the disease, from 6.7 months to 13.2 months. The full results from the company's final-stage trial are expected to be the star of the show at the annual confab of cancer doctors in Chicago this weekend.Spurred by the success of RevMed, numerous companies are now racing to develop similar drugs, dubbed "molecular glues", which can be used to treat a variety of ailments. And investors and pharmaceutical companies with deep pockets are chasing after them, creating one of the hottest corners of dealmaking in the industry.Also read | India's out-of-pocket healthcare spending drops significantly, govt data showsIt's not unusual for exciting new drugs to spark surges in stock prices and dealmaking frenzy. But molecular glue is a particularly complicated science, and the startups pursuing technologies similar to RevMed are mostly in early stages of testing. Their medicines won't be ready for years, if ever.That hasn't stopped big drugmakers such as Novartis, Roche Holding and Eli Lilly from inking research pacts with glue developers that could pay out billions of dollars in milestones.The boom has been especially lucrative for Monte Rosa Therapeutics. Over the past three years, the Boston-based biotech firm has signed three agreements that could be worth over $10 billion to develop molecular glue drugs with both Novartis and Roche.The company, which trades under the stock ticker GLUE, has seen its shares surge nearly 400% over the past year. It's preparing to start mid-stage trials for multiple drugs by the end of this year."The run-up in the share price is justified based on what we've seen so far," says Robert Driscoll, an analyst at Wedbush. Gains are "due to the success of their drugs rather than kind of exuberance around the glue technology as a whole", he says.Science of GlueMolecular glues work in a fundamentally different way from other oral medicines. Most pills - like Prozac for depression or Lipitor for cholesterol - are tiny chemicals that squeeze into a pocket inside a much larger protein to gum up its functioning. But many proteins have few obvious pockets, including key cancer-causing proteins.In fact, about 80% of all proteins in the body are what scientists refer to as "undruggable", meaning they can't be targeted with traditional drug technologies.RevMed's daraxonrasib cleverly circumvents this problem by acting as a molecular stickum. Once inside the body it binds to a healthy protein on one side and then draws in the bad protein to stick to the other side. The healthy protein helps block the bad protein and turn off its signalling.Competitors Line UpMultiple companies are chasing RevMed's lead in pancreatic cancer despite the long odds. San Diego-based Erasca is in early stages of testing a drug it says is more potent than daraxonrasib. Japanese drugmaker Astellas Pharma has begun final-stage trials of a degrader that may help a subset of pancreatic and lung cancer patients.Molecular glues are also being developed as alternatives to injectable drugs used to treat autoimmune and skin disorders. Shares of Kymera Therapeutics have soared more than 180% in the past year thanks to promising early trial results. The company is developing a once-daily pill it hopes will one day compete with Sanofi and Regeneron Pharmaceuticals' Dupixent, one of the world's bestselling drugs."The technology allows you to go after things that would have been almost impossible" to do previously with pills, says Nello Mainolfi, Kymera's founder and CEO.With few effective options for pancreatic cancer, analysts expect RevMed's daraxonrasib to become an enormous bestseller for the company.Prospects for daraxonrasib and speculation about a potential takeout deal have inflated RevMed's market cap to nearly $33 billion. That's a lofty figure for a drugmaker with no approved medicines.The company is preparing to file for US approval soon, and the FDA has promised to give the drug an ultrafast review. It's projected to reach $7 billion in sales a year by 2032, according to the average of estimates compiled by Bloomberg.

How Pigeons Use Iron-Rich Liver Cells To Find Their Way Home

Specialized immune cells in the pigeon's liver break down red blood cells and store iron

ICE detainees at New Jersey jail were beaten and pepper-sprayed in their cells, officials and families say

Protests continue outside Delaney Hall as hunger strike over conditions inside enters a second week

For Congenital Deafness, a Chinese Trial Opens a Path to Sound

The world’s first clinical trial on congenital deafness gene therapy showed that injecting a missing gene back into ear cells can restore hearing.

How pigeons exploit magnetic fields for navigation

Iron-rich immune cells in the liver may act as sensors for magnetic fields, serving as an internal compass.

LG Energy Solution rides AI power surge with $1.6b US battery deal

LG Energy Solution has secured its second large-scale US energy storage system battery supply deal, as part of its push to capture fast-growing power demand from artificial intelligence data centers and grid infrastructure while navigating a prolonged slowdown in the electric vehicle sector. According to LG Energy Solution on Thursday, it signed a $1.6 billion contract with Michigan-based utility giant DTE Energy to supply 6 gigawatt-hours of ESS batteries for two years. The battery cells will p

India Clears First Hydrogen-Powered Train On Jind-Sonipat Route In Green Rail Push | Details

The hydrogen powered train will run on the Jind Sonipat route in Haryana. Unlike conventional trains, it will generate electricity onboard through hydrogen fuel cells.

TV tonight: Richard Madeley enters El Salvador’s terrifying mega-prison

The presenter visits the controversial Cecot jail. Plus: Anne discovers the true cost of babysitting in Amandaland. Here’s what to watch this evening 9pm, Channel 5 If you can get over the idea of Alan Partridge being let loose in one of El Salvador’s most controversial prisons, Richard Madeley’s visit to the notorious Cecot is a genuinely chilling experience. He finds thousands of men silently sitting on stacked beds in cells that are lit 24 hours a day. When he asks about conditions, he is told to leave. But after learning more about the nation’s gang history, and how Trump has made use of the prison, Madeley returns … Hollie Richardson Continue reading...